113 results
-
List item
Opinion/decision on a Paediatric investigation plan (PIP): Latuda, Lurasidone hydrochloride
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Psychiatry
PIP number: EMEA-001230-PIP01-11-M05, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 04/11/2019, Last updated: 21/09/2021, Compliance check: V, 11/12/2019AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. S.p.A … Tel. +3906780531 E-mail: angeliniregulatoryaffairs@angelinipharma.com Decision type PM: decision … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): benzydamine (hydrochloride), econazole nitrate
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: EMEA-002143-PIP01-17, Route(s) of administration: Vaginal use, Pharmaceutical form(s): Pessary
Decision date: 30/06/2017, Last updated: 25/07/2017, Compliance check: XAziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A … 0691045249 E-mail: ma.gatto@angelini.it ; m.gatto angelini.it W: decision granting a … Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A … -
List item
Human medicine European public assessment report (EPAR): Ontozry
cenobamate, Epilepsy
Date of authorisation: 26/03/2021,
, Revision: 3, Authorised, Last updated: 21/03/2022
-
List item
Opinion/decision on a Paediatric investigation plan (PIP): Trazodone (hydrochloride), gabapentin
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Pain
PIP number: EMEA-002263-PIP01-17, Route(s) of administration: Oral use, Pharmaceutical form(s): Capsule, hard
Decision date: 16/03/2018, Last updated: 19/06/2018, Compliance check: XAziende Chimiche Riunite Angelini Francesco - A.C.R.A.F … 0691045249 E-mail: m.gatto@angelini.it W: decision granting … Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Trazodone (hydrochloride)
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Neurology
PIP number: EMEA-002142-PIP01-17, Route(s) of administration: Oral use, Pharmaceutical form(s): Age-appropriate oral liquid dosage form
Decision date: 19/12/2017, Last updated: 05/03/2018, Compliance check: XAziende Chimiche Riunite Angelini Francesco - A.C.R.A.F - S.p.A … 0691045249 E-mail: m.gatto@angelini.it P: decision agreeing on … Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F … -
List item
Human medicine European public assessment report (EPAR): Latuda
lurasidone, Schizophrenia
Date of authorisation: 21/03/2014, Revision: 25, Authorised, Last updated: 17/03/2022 -
List item
National expert: Francesca Galeotti, Italian Medicines Agency (updated)
- Declaration of interests - 80.12 KB | PDF
- Curriculum Vitae - 22.13 KB | PDF
Type of Interest Declared Angelini, Grunenthal Consultancy 2.9 … -
List item
National expert: Nigel Olisa, European Medicines Agency (updated)
- Declaration of interests - 80.28 KB | PDF
- Curriculum Vitae - 16.55 KB | PDF
Ingelheim, Teva, Servier, Angelini, Compass Pathways All supporting … -
List item
National expert: Tiziana Mongini, Italian Medicines Agency (updated)
- Declaration of interests - 81.6 KB | PDF
- Curriculum Vitae - 32.71 KB | PDF
-
List item
National expert: Emilio Perucca, Italian Medicines Agency (updated)
- Declaration of interests - 86.11 KB | PDF
- Curriculum Vitae - 109.64 KB | PDF
epilepsy 07/2021-(current) Angelini cenobamate epilepsy 01/2021-(current … editorial activities, speaker Angelini Consultant, Advisory Board … -
List item
National expert: Serena Zamponi, Italian Medicines Agency (updated)
- Declaration of interests - 80.37 KB | PDF
- Curriculum Vitae - 17.71 KB | PDF
development trainee ACRAF S.p.a. - Angelini (Italy) - Pre-formulation … -
List item
National expert: Diego Alejandro Dri, Italian Medicines Agency (updated)
- Declaration of interests - 80.88 KB | PDF
- Curriculum Vitae - 20.99 KB | PDF
Type of Interest Declared Angelini Acraf S.p.A. Spouse working … -
List item
National expert: Georgios Papazisis, National Organization for Medicines (updated)
- Declaration of interests - 80.18 KB | PDF
- Curriculum Vitae - 37.77 KB | PDF
Interest Aziende Chimiche Riunite Angelini Francesco SpA honoraria 2.5 … -
List item
Human medicine European public assessment report (EPAR): Xydalba (updated)
dalbavancin hydrochloride, Soft Tissue Infections; Skin Diseases, Bacterial
Date of authorisation: 19/02/2015, Revision: 14, Authorised, Last updated: 29/07/2022 -
List item
National expert: Fiorentino Capozzoli, Italian Medicines Agency (updated)
- Declaration of interests - 80.02 KB | PDF
- Curriculum Vitae - 19.36 KB | PDF
INFORMATION Expertise Publications 1) Angelini R, Capozzoli F, Lepore P … -
List item
National expert: Alessandra Spagnoli, Italian Medicines Agency (updated)
- Declaration of interests - 79.8 KB | PDF
- Curriculum Vitae - 32.51 KB | PDF
-
List item
Human medicine European public assessment report (EPAR): Akynzeo
netupitant, palonosetron hydrochloride, Vomiting; Neoplasms; Nausea; Cancer
Date of authorisation: 27/05/2015, Revision: 13, Authorised, Last updated: 21/02/2022 -
List item
National expert: Juan Pablo Horcajada, European Medicines Agency (updated)
- Declaration of interests - 82.11 KB | PDF
- Curriculum Vitae - 22.79 KB | PDF
speaker fee 01/2021-06/2021 Angelini speaker fee 11/2021-11/2021 … -
List item
National expert: Annamaria Staiano, European Medicines Agency (updated)
- Declaration of interests - 82.29 KB | PDF
- Curriculum Vitae - 21.71 KB | PDF
consultant 06/2020-(current) Angelini Consultant 01/2021-(current … -
List item
National expert: Georgia Valsami, National Organization for Medicines (updated)
- Declaration of interests - 80.53 KB | PDF
- Curriculum Vitae - 47.21 KB | PDF
of Athens, Pharmaten S.A., Angelini S.A., aViPharma S.A. (completed … -
List item
Human medicine European public assessment report (EPAR): Myozyme
alglucosidase alfa, Glycogen Storage Disease Type II
Date of authorisation: 28/03/2006, Revision: 19, Authorised, Last updated: 13/12/2021 -
List item
National expert: Pascal Laforet, European Medicines Agency (updated)
- Declaration of interests - 82.45 KB | PDF
- Curriculum Vitae - 21.79 KB | PDF
ME, Toscano A, Laforet P, Angelini C, Lachmann RH, Pascual Pascual … -
List item
Human medicine European public assessment report (EPAR): Helicobacter Test INFAI
urea (13C), Breath Tests; Helicobacter Infections
Date of authorisation: 14/08/1997, Revision: 18, Authorised, Last updated: 03/05/2021 -
List item
Human medicine European public assessment report (EPAR): Peyona (previously Nymusa)
Caffeine citrate, Apnea
Date of authorisation: 02/07/2009, Revision: 13, Authorised, Last updated: 22/12/2021 -
List item
Human medicine European public assessment report (EPAR): Pravafenix
fenofibrate, Pravastatin, Dyslipidemias
Date of authorisation: 14/04/2011, Revision: 6, Authorised, Last updated: 17/03/2021